Table 1.
Current oncolytic clinical trials for cancers affecting the head and neck.
| ClinicalTrials.gov ID | Oncolytic agent | Combination | Phase | IT versus IV | Disease |
|---|---|---|---|---|---|
| NCT02428036 | TBI-1401(HF10) (HSV-1) | No | Phase I | IT | SCC skin Melanoma |
| NCT02272855 | TBI-1401(HF10) (HSV-1) | Ipilimumab | Phase II | IT | Stage IIIB, Stage IIIC, or Stage IV Unresectable or Metastatic Malignant Melanoma |
| NCT00769704 | TVEC (HSV-1) | No | Phase III | IT | Unresectable Stage IIIb, IIIc and IV Disease |
| NCT01368276 | TVEC (HSV-1) | No | Maintenance | IT | Unresectable Stage IIIb, IIIc and IV Disease |
| NCT01740297 | TVEC (HSV-1) | Ipilimumab | Phase Ib | IT | Unresectable melanoma |
| NCT00931931 | HSV1716 (HSV-1) | No | Phase I | IT | Refractory non-central nervous system (Non-CNS) solid tumors |
| NCT01166542 | Reolysin (Reovirus) | Paclitaxel and Carboplatin | Phase III | IV | Metastatic or recurrent SCC |
| NCT01846091 | MV-NIS (Measles virus) | No | Phase I | IT | Recurrent or metastatic SCC |
| NCT01584284 | GL-ONC1 (Vaccinia) | Cisplatin and radiation | Phase I | IV | Locally advanced H&N SCC |
| NCT00429312 | JX-594 (Vaccinia) | No | Phase I/II | IT | Stage III/IV unresectable melanoma |
| NCT00438009 | CVA21 (Coxsackievirus Type A21) | No | Phase I | IT | Stage IV melanoma |
IT, intratumoral; IV, intravenous; SCC: squamous cell carcinoma.